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Abstract: Food allergy poses a significant burden on patients,
families, health care providers, and the medical system. The in-
creased prevalence of food allergy has brought about investigation
as to its cause and new treatments. Currently, the only treatment
available is to avoid the food and symptomatically treat any reac-
tions. There are multiple clinical and murine models of food allergy
treatment that use allergen specific and nonspecific pathways. Al-
lergen specific treatments use mucosal antigen exposure as a method
of inducing desensitization and tolerance. Allergen nonspecific
methods act via a more global TH2 suppressive mechanism and may
be useful for those patients with multiple food allergies.
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INTRODUCTION
The incidence of atopic disease (asthma, eczema, allergicrhinitis, and food allergy) has significantly increased in
Western countries over the last half century,1 although there
is some evidence of its stabilization.2 The prevalence of food
allergy, in particular, has increased3 that places a large burden
on affected patients and their families. It is estimated that
food allergy affects 6% of children younger than 3 years old
and 4% of adults.4 There is no clear reason to this increas-
ing prevalence, but many theories including increased hy-
giene, increased dietary fat, antioxidants, vitamin D insuffi-
ciency, and skin sensitization have been proposed.5 The
impact on the overall medical system is significant. There are
an estimated 125,000 emergency room visits related to food
allergy in the United States with about 15,000 of these
secondary to food induced anaphylaxis.6 Food allergy not
only affects the patient, but the whole family as well. Child-
hood food allergy has a significant impact on general health
perception, emotional impact on the parent, and limitation on
family activities.7 It has also been shown that the diagnosis of
food allergy causes significant alterations in meal prepara-
tion, social activities, and school attendance and contributed
to increased stress levels in the family.8 The possible mech-
anisms of food allergy are under investigation and need
further elucidation. Alterations in the normal development of
tolerance can be the product of a failure to establish oral
tolerance or a breakdown in existing tolerance skewing the
immune system to a TH2 response to these proteins9,10. In this
article, we will review the current standard of therapy and
explore possible future management for food allergy.
CURRENT THERAPY
Currently, the only treatment for food allergy is avoid-
ance of the allergen.11 Hidden allergens in foods represent a
significant problem in manufactured foods. The presence of
undeclared allergens in food products represents one of the
more common reasons for food product recall in the United
States.12 Of all the food products recalled in 1999, 36% were
recalled because they contained one or more undeclared
allergens. Although the Food Allergen Labeling and Con-
sumer Protection Act (FALCPA) has been adopted, food
packaging and formulation errors, ingredient switching, and
foods not covered under this legislation continue to be
sources of hidden food allergens.13 Accidental ingestions also
pose a significant threat with events occurring in more than
50% of peanut allergic and in 30% of tree nut allergic
children.14
The majority of food allergy related deaths are second-
ary to accidental ingestions of peanuts and tree nuts.15 Reac-
tions secondary to food allergy must be recognized quickly to
ensure the timely administration of epinephrine to prevent
fatality.11 Adolescent food allergic patients with comorbid
asthma and without access to epinephrine are more likely to
have a fatal anaphylaxis reaction.15 Certain physiologic risk
factors (eg, decreased PAF acetylhydrolase activity) have
been found that may be used to identify those patients at
higher risk for severe anaphylaxis to food.16
PRIMARY PREVENTION
Currently, many international allergy/immunology so-
cieties have backed away from recommending long-term
dietary restriction during early infancy. In 2008, the Ameri-
can Academy of Pediatrics published its latest statement on
early nutritional interventions and their effect on allergy.
They found that breast-feeding for at least 4 months can
prevent or delay atopic dermatitis, cow’s milk allergy, and
wheezing in early life. In addition, there was insufficient data
to support maternal dietary restrictions during pregnancy and
lactation or any dietary intervention beyond 4 to 6 months of
age.17
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There is also significant data showing that dietary
restrictions may actually increase the risk of atopic dis-
ease.18,19 A major difference of this report versus previous
versions is that it does not make recommendations. Instead,
statements about possible dietary changes are made along
with the presence or absence of its effectiveness. It is impor-
tant to note that although current evidence does not exist for
some of these techniques (ie, any dietary intervention beyond
4 to 6 months of life) that does not necessarily mean that they
will prove to be inefficacious with further study.20
There is some evidence that supplementing breast-
feeding with a hydrolyzed formula in at risk infants may
prevent some allergic disease.21 The German Infant Nutri-
tional Intervention (GINI) Study was a prospective trial of a
large number of children with high risk of developing atopic
disease. These infants were randomized to receive either
cow’s milk based formula or 1 of 3 hydrolyzed formulas as
breast milk supplements for the first 4 months of life. The
relative risk of a physician’s diagnosis of allergic manifesta-
tion compared with cow’s milk formula was 0.82 (95% CI,
0.70–0.96) for partially hydrolyzed whey formula, 0.90
(95% CI, 0.78–1.04) for extensively hydrolyzed whey for-
mula, and 0.80 (95% CI, 0.69–0.93) for extensively hydro-
lyzed casein formula.
The timing of introduction of foods has also been
examined as a factor leading to food allergy. Lack et al have
shown that the prevalence of peanut allergy in Jewish chil-
dren from England is 10-fold higher than that of Jewish
children in Israel.22 Because Israeli infants are introduced to
peanut during early weaning and continue to eat peanut more
frequently and in higher amounts than English infants, this
same group questions whether early introduction of peanut
during infancy, rather than avoidance, will prevent the devel-
opment of peanut allergy. They are currently testing this
hypothesis through the Learn Early About Peanut Allergy
(LEAP) study that is a randomized, controlled trial of infants
at high risk of developing peanut allergy (those with eczema
and egg allergy) who avoid peanut or eat an age appropriate
peanut snack. The primary outcome is to compare the rates of
peanut allergy development between the 2 cohorts.
ALLERGEN SPECIFIC IMMUNOTHERAPY
Potential treatment modalities for food allergy can be
categorized as either allergen specific or allergen nonspecific
immunotherapy (Table 1). Traditionally allergen specific im-
munotherapy has focused on antigen delivery to the immune
system subcutaneously. Unfortunately, clinical trials of this
type of food allergy treatment were shown to be impractical
and unsafe.23,24 Mucosal allergen specific immunotherapy via
the sublingual or oral route is accomplished via administering
small but increasing doses of food protein in a controlled
setting. This is followed by daily home doses of the maxi-
mum tolerated amount. An important distinction must be
made between desensitization and tolerance. The threshold
dose represents the amount of food protein the immune
system must encounter to initiate an allergic reaction. Desen-
sitization is the act of increasing the threshold dose to prevent
life threatening anaphylaxis. This effect can be short term or
prolonged with ongoing therapy. Physiologically this can be
accomplished from an increase in food specific IgG4 and a
decrease in food specific IgE, this antibody profile can then
lead to decreased mast cell and basophil activation and
decreased release of inflammatory mediators. It is also pos-
sible that desensitization is due, in part, to intrinsic changes in
the mast cell and basophil. Tolerance refers to the active
adaptation of the immune system via increased Treg devel-
opment and skewing away from a TH2 profile, leading to
resolution of the allergy.10
TABLE 1. Potential Strategies for Treating Food Allergy
Therapy Mechanism Status
Allergen specific
Sublingual immunotherapy Controlled prolonged exposure to antigen promotes switch
from Th2 to Th1 response via promotion of Treg activity
Clinical trials
Oral immunotherapy Controlled prolonged exposure to antigen promotes switch
from Th2 to Th1 response via promotion of Treg activity
Clinical trials
Heat denatured protein “Natural” immunotherapy by presenting linear but not
conformational epitopes to tolerant patients
Clinical trials are
on-going
Engineered protein immunotherapy Mutated IgE-binding epitopes prevent allergic reaction
while maintaining T cell activity
Early stage clinical trials
Peptide vaccine T cell epitope preservation while preventing IgE-cross
linking via small overlapping peptides
Murine models




Promote Th1 response via activation of innate immune
pathway (toll-like receptors)
Clinical trials with allergic rhinitis
Allergen nonspecific
Monoclonal anti-IgE therapy Binds and inactivates IgE and prevents stimulation of high
affinity IgE-receptor
Monotherapy studies not active, combination
studies with other therapies in clinical trials
Chinese herbal medicine Unknown mechanism, not steroid effect Early stage clinical trials
Cytokine therapy Interfere with inflammatory pathways Clinical trials for eosinophilic esophagitis
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Sublingual Immunotherapy
This therapy uses small amounts of liquid that contain
the relevant protein. The drops are held under the tongue for
a specified amount of time and then either swallowed or
discharged. Enrique et al studied 23 patients with hazelnut
allergy confirmed by double-blinded, placebo-controlled food
challenges (DBPCFC) who received sublingual immunother-
apy (SLIT) with either hazelnut extract or placebo.25 Of note,
almost half of these subjects had symptoms most consistent
with oral allergy syndrome. The maintenance treatment de-
livered 188 g of Cor a 1 and 122 g of Cor a 8 to the
sublingual mucosa that was held for 3 minutes then dis-
charged. After 8–12 weeks, a subsequent food challenge
revealed a significant increase in threshold dose to symptoms
in treatment patients versus placebo. The mean hazelnut dose
provoking symptoms increased from 2.29 g to 11.56 g in the
active group (P 0.02) versus 3.49 g to 4.14 g in the placebo
subjects (not significant). Almost 50% of patients who un-
derwent treatment reached the highest dose (20 g), but only
9% in the placebo. Oral pruritis occurred in 7.4% of all doses,
while systemic reactions were observed in only 0.2% of the
total doses administered. Mechanistic assays showed an in-
crease in IgG4 and IL-10 levels after immunotherapy in only
the active group, but there was no change in the hazelnut-
specific IgE. These results provide some evidence for the
efficacy of SLIT, but many of the patients had symptoms
of oral allergy syndrome. It is unclear whether these
findings support SLIT for true food allergy versus oral
allergy syndrome.
Currently there are multiple ongoing randomized pla-
cebo-controlled studies looking at treating other food aller-
gies with SLIT. An ongoing randomized, placebo controlled
study we are conducting at Duke University uses SLIT to
treat peanut allergic children. The National Institutes of
Health sponsored Consortium of Food Allergy Research
(CoFAR) is also conducting a randomized, placebo-con-
trolled study of peanut SLIT in peanut allergic adults. In both
of these studies, subjects hold their doses sublingually for 2
minutes and then swallow (vs the Enrique protocol).
Oral Immunotherapy
This treatment entails oral ingestion of the protein
mixed in a food vehicle. Induction of desensitization was
demonstrated in the majority of 47 food allergy subjects that
underwent 54 oral desensitizing treatments using standard-
ized protocols.26 Some of the patients had multiple food
allergies confirmed by DBPCFC and participated in multiple
desensitizations. The majority of patients (83.3%) success-
fully completed the treatment. During treatment, 51.1% of
subjects experienced some mild side-effects, which were
controlled by the oral administration of antihistamines or
sodium cromolyn. Compared with age and sex matched
controls who followed a strict elimination diet, subjects
undergoing oral immunotherapy (OIT) had a significant de-
crease in food-specific IgE and increase in IgG4. These
immunologic findings led the authors to hypothesize that oral
tolerance may be mediated by the same mechanisms as those
involved in traditional immunotherapy that is used for respi-
ratory allergies.
Buchanan et al published a successful OIT protocol for
egg allergic children.27 Seven children with egg allergy di-
agnosed by an in vitro egg-specific IgE of 7 kU/L or greater
(2 kU/L or greater for subjects 2 years of age) or with a
positive allergic reaction to egg within 6 months of beginning
the study were recruited. These subjects underwent a 24
month egg OIT protocol involving a modified rush, build-up,
and maintenance phases. A maintenance dose of 300 mg was
used. During the initial DBPCFC on the day maintenance
therapy ended, 4 of the 7 patients tolerated 14.7 g of egg
protein. Subjects who passed the first challenge underwent a
second DBPCFC after a 3 to 4 month interval without OIT,
during which they maintained an egg-restricted diet. Two of
these subjects passed the second challenge that demonstrated
evidence for tolerance induction, but could also represent the
subject’s naturally outgrowing egg allergy. At the end of the
treatment period egg-specific IgG concentrations increased
significantly, although egg-specific IgE concentrations did
not change. Symptoms related to dosing were generally mild
and required at most treatment with oral diphenhydramine.
Some investigators have questioned whether results
like this represent the spontaneous resolution of allergy es-
pecially in egg and milk allergic subjects. In a randomized,
controlled study, 45 egg or cow’s milk allergic patients
underwent OIT with 4.5 g of egg or 250 mL (8.5g) of milk,
respectively, or were continued on an elimination diet.28 All
treated subjects experienced side effects during the dose
escalation and on maintenance therapy, although the authors
considered the great majority of these symptoms as mild. At
the follow up food challenge (after 2 months of an elimina-
tion diet in the OIT subjects) 9 of 25 children (36%) showed
tolerance in the treatment and in the control group, 7 of 20
children (35%) were tolerant. These results suggested that the
effect of OIT was comparable to the rate of natural sponta-
neous resolution of allergy. However, an additional 7 of 25 in
the treatment group had some level of partial response that
could infer protection from accidental ingestion. This would
increase the rate of responders to 64%.
More recently, a randomized, placebo controlled study
of milk OIT in milk allergic subjects was conducted that
produced different results.29 Twenty milk allergic subjects
confirmed by DBPCFC were randomized to milk OIT or
placebo. Dosing included 3 phases: the build-up day (initial
dose, 0.4 mg of milk protein; final dose, 50 mg), daily doses
with 8 weekly dose increases to a maximum of 500 mg, and
continued daily maintenance doses for 3 to 4 months. Nine-
teen patients, 6 to 17 years of age, completed treatment: 12 in
the active group and 7 in the placebo group. One dropped out
because of persistent eczema during dose escalation. The
subsequent food challenge at the end of the maintenance
period showed an active group threshold symptom dose much
higher that the placebo group (5,140 mg vs 40 mg, P 
0.0003). Among treatment doses versus placebo, there were
45.4% versus 11.2% total reactions, with local symptoms
being most common. Interestingly, milk-specific IgE did not
change, but milk-specific IgG4 increased significantly.
Among the placebo subjects, 6 of 7 elected to receive open
label active treatment after the unblinding DBPCFC. In those
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patients, the milk dose threshold was 40 mg before OIT. After
OIT, the median was 8,140 mg (P  0.03). These results
provide strong evidence for desensitization for this milk OIT
protocol.
Similar results have been seen in an ongoing random-
ized, placebo controlled study of peanut OIT in peanut
allergic children taking place at Duke University and the
University of Arkansas for Medical Sciences. Thirty-seven
peanut allergic subjects between the ages of 1 to 18 years old
have been enrolled in this protocol with a maintenance dose
of 4000 mg of peanut protein or placebo. There have been 2
subjects that have failed to reach the maintenance dose. Both
of these subjects were initial day desensitization failures
where allergic symptoms were not tolerated. After 1 year, all
treatment subjects have tolerated 5000 mg of peanut protein
during food challenge compared with placebo patients who
tolerated a median dose of 460 mg (P  0.001). After 6
months on therapy the mean titrated skin prick test (SPT) and
basophil activation have decreased significantly in the treat-
ment group (unpublished data). Mechanistic assays from an
earlier open label trial of peanut oral immunotherapy dem-
onstrated that the mean peanut-specific IgE initially increased
but then decreased at 12 and 18 months. The peanut-specific
IgG4 increased to a peak at 24 months and the number of
FoxP3 Tregs also increased to a peak at 12 months.30
These initial results suggest that food specific OIT is
safe and effective in attaining desensitization. Although de-
sensitization in itself is better than complete avoidance, the
induction of tolerance would be the ultimate goal. The ability
of these therapies to induce tolerance is currently the focus of
ongoing investigations. For a summary of selected SLIT and
OIT studies refer to Table 2.
Heat Denatured Protein
High heat reduces the allergenicity of many food pro-
teins by altering the conformation of heat-labile proteins and
eliminating conformational epitopes.31 Patients with persis-
tent milk allergy possess higher detectable levels of IgE
antibodies to linear epitopes from casein than patients who
have achieved tolerance.32 Lemon-Mule et al demonstrated
that of 117 subjects with documented IgE mediated allergy to
egg, 27 were heated egg reactive, 64 were heated egg toler-
ant, 23 were egg (heated and unheated) tolerant.33 Thus, 70%
of children with egg allergy were tolerant to heated egg.
Those subjects who ingested heated egg after passing the egg
challenge had significant decreases in their egg white SPTs
(P  0.001), increased ovalbumin and ovomucoid-specific
IgG4 levels from baseline at 3, 6, and 12 months (P 0.001),
and decreased ovalbumin-specific IgE levels at 12 months
(P  0.001). Of note, the egg white and ovomucoid-specific
IgE levels did not differ from baseline.
The same group looked at 100 milk allergic children
and found that 68 tolerated extensively heated milk only, 23
reacted to heated milk, and 9 tolerated both heated and
unheated milk.34 Overall 78% of the children tolerated heated
milk. The subjects who tolerated extensively heated milk, but
reacted to unheated milk were placed on a diet containing
baked milk products. Immunologically, these subjects at 3
months had smaller median milk SPT diameters (P  0.001)
and an increase in median casein-specific IgG4 concentra-
tions (P  0.005). There was no change seen in median
casein and -lactoglobulin-specific IgE, -lactoglobulin-spe-
cific IgG4, or milk-specific IgE levels.
The implications from this study could mean that those
heated-antigen tolerant patients may actually have an accel-
erated course to tolerance by ingesting the implicated heated
food. This form of immunotherapy is still under investigation,
but it may represent another avenue of treatment.
Engineered Antigen
One approach to immunotherapy is to create engi-
neered (mutated) proteins in which the IgE-binding
epitopes are altered thereby decreasing the allergenicity
whereas sparing the protein’s ability to stimulate antigen-






Enrique et al.25 Hazelnut (11) 8–12 weeks Five (45%) of 11 reached highest dose (20 g) in food challenge.
Bird et al. (ongoing) Peanut (7) 30 months At 4 months, no significant change in peanut-specific IgE, IgG, IgG4,
or skin prick wheal diameter.
Oral
Patriarca et al.26 Varied (24) 18 months Desensitization was successful in 45 (77%) of 58 treatments.
Buchanan et al.27 Egg (7) 24 months Four (57%) of 7 passed food challenge with 14.7 g of egg at conclusion
of therapy; 2 passed second challenge 3–4 months later.
Staden et al.28 Cow’s milk or egg (45) 11–59 months Nine of 25 children (36%) showed tolerance in the treatment and in
the control group, 7 of 20 children (35%) were tolerant.
Skripak et al.29 Cow’s milk (19) 5–6 months Eight out of 19 (42%) passed food challenge with 8 g of milk.
Treatment subjects who underwent a posttreatment challenge
had significant median increase in threshold dose.
Jones et al.30 Peanut (29) 18 months Twenty-seven of 29 (93%) passed food challenge to 3.9 g of peanut.
Varshney et al. (ongoing) Peanut (27) 1 year All treatment subjects that have undergone food challenges have
tolerated 5 g of peanut.
Adapted from Burks et al. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008;121:1348.
WAO Journal • December 2009 Managing Food Allergy
© 2009 World Allergy Organization 285
specific T cells. There have been several recombinant food
proteins created.35–37 One in vivo study using a murine model
has demonstrated efficacy in preventing peanut induced ana-
phylaxis.37 Peanut-allergic C3H/HeJ mice received heat-
killed Escherichia coli producing engineered (mutated) Ara
h1, 2, and 3 (HKE-MP123) rectally. The medium- and high-
dose HKE-MP123-treated mice exhibited reduced symptom
scores on subsequent peanut challenges for up to 10 weeks
after treatment accompanied by a significant reduction of
plasma histamine levels compared with sham-treated mice
(P 0.05 and .01, respectively). IgE levels were significantly
lower in all HKE-MP123–treated groups (P  0.001). Phase
I clinical trials are presently ongoing.
Peptide Immunotherapy
Small peptides cannot cross-link IgE bound to mast cells,
so degranulation would not occur. Theoretically, a vaccine
composed of overlapping small peptides that span the sequence
of allergenic proteins could present epitopes to T cells without
causing an allergic response. Although preliminary murine mod-
els of this strategy have shown promise, validating the stability
and uniformity of a complex vaccine has proven to be difficult
and has thus hindered development.11
Plasmid DNA
By creating vaccines that use bacterial plasmid DNA
that encode an allergen, it is hypothetically possible to induce
tolerance by the production of endogenously produced anti-
gens that would not stimulate an allergic response. Oral
administration of plasmid DNA complexed with chitosan, a
natural biocompatible polysaccharide, resulted in the preven-
tion of peanut allergy in AKR/J mice.38 Mice receiving these
DNA nanoparticles containing Ara h 2 produced secretory
IgA and serum IgG2a and had reduced levels of IgE, plasma
histamine and vascular leakage. However, a later study found
that AKR/J, but not C3H/HeJ mice, were protected from
peanut allergy using intramuscular injections of plasmid
DNA encoding Ara h 2.39 The different outcomes for these
different strains of mice call in to question the effectiveness
of this therapy in clinical trials.
Allergen-Conjugated Immune Stimulatory
Sequences
Another strategy employs the use of allergen determi-
nants that augment TH1 responses via the innate immune
system. Certain pathogen associated molecular patterns
(PAMPs) can act as immune stimulatory sequences that
enhance the TH1 response thus skewing the immune system
away from a TH2 phenotype. Nguyen et al found that using a
vaccine with the immunostimulatory sequence oligode-
oxynucleotide on subsequently TH2-sensitized mice signifi-
cantly reduced the risk of death after anaphylactic chal-
lenge.40 This strategy may be effective in preventing allergy,
but its value at treating ongoing food allergy in still in
question.
ALLERGEN NONSPECIFIC IMMUNOTHERAPY
An alternative approach to food allergy is to more
globally suppress the TH2 response rather than treating the
protein specific reaction. For those patients with multiple
food allergies, this could prove to be invaluable.
Anti-IgE Therapy
Leung et al used the humanized monoclonal anti-IgE
molecule TNX-901 in a double-blinded, placebo-controlled
trial of peanut allergy.41 Different doses of TNX-901 were
given subcutaneously for 16 weeks to subjects with proven
peanut allergy from baseline food challenge. The highest
dose (450 mg) of TNX-901 significantly increased the thresh-
old dose from 178 mg to 2.8 g (P  0.001). Unfortunately,
25% of participants received no benefit and no biomarkers or
parameters were identified that could distinguish responders
from nonresponders.
A subsequent double-blinded, placebo-controlled study
using another monoclonal anti-IgE molecule, omalizumab, in
peanut allergic subjects for 20–22 weeks was discontinued
because of safety concerns related to the pre-omalizumab
challenges. Limited data showed possible increase in toler-
ance of omalizumab versus placebo treated subjects (44.4%
vs 20% tolerated 500 mg peanut protein). More studies are
needed to elucidate this treatment modality.
Chinese Herbal Medicine
A mixture of 9 traditional Chinese herbs, named Food
Allergy Herbal Formulation-2 (FAHF-2), has shown promis-
ing results in a murine model of allergy.42–44 Mice allergic to
peanut treated with FAHF-2 for 7 weeks were challenged 1,
3, or 5 weeks posttherapy. After challenges, all sham-treated
mice developed severe anaphylactic signs while no sign of
anaphylactic reactions was observed in FAHF-2-treated mice.
IgE levels were significantly reduced by FAHF-2 treatment
and remained significantly lower as long as 5 weeks post-
therapy.42 In a follow up study, C3H/HeJ mice previously
sensitized to peanut were treated with 7 weeks of FAHF-2 or
sham treatment.43 Mice were subsequently challenged 1 day
posttherapy and 4 weeks posttherapy. All sham-treated mice
showed anaphylactic symptoms on the subsequent challenges
versus the FAHF-2-treated mice that showed no sign of
anaphylactic reactions. Peanut-specific IgE levels in FAHF-
2-treated mice also were reduced (4 weeks posttherapy, P 
0.001) whereas IgG2a levels were increased (4 weeks post-
therapy, P  0.001). More recently, the same group has now
shown that the protective effect of 7 weeks of FAHF-2 on
mice lasts more than 36 weeks.44 They also found that the
beneficial effect of FAHF-2 is mediated largely by elevated
CD8 T-cell IFN- production. Phase I human trials are
currently ongoing.
Cytokine Therapy
It has been shown that the administration of a Lacto-
coccus lactis transfected to secrete IL-10 prevented sensiti-
zation in a mouse model of food allergy.45 IL-10 is a known
suppressive regulatory cytokine. The administration of re-
combinant mouse IL-21 or an IL-21 expression plasmid
suppressed anaphylaxis in mice previously sensitized to pea-
nut.46 IL-21 was shown to regulate systemic allergic reactions
by inducing the transcriptional regulator Id2, which blocks B
cell class switch recombination and IgE production. TGF-ß
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may also prove to be an effective immune modulator for food
allergy. BALB/c mice treated orally with ovalbumin and
TGF- showed reduction of ovalbumin-specific IgE and
IgG1 antibodies, T-cell reactivity, and immediate-type skin
reactions when compared with the mice treated orally with
ovalbumin alone.47 Li et al demonstrated that an increase of
TGF- protein in BALB/c mouse intestinal tissue can be
induced after oral administration of a TGF- expressing
DNA vector that was packed in chitosan nanoparticles.48 A
significant amelioration of ovalbumin-induced food allergy
symptoms was also shown. Cytokine therapy holds a great
potential, but it requires further investigation.
ALTERNATIVE THERAPIES
Other strategies targeting specific immune pathways
have emerged in murine models that may hold promise.
Blocking the interaction between dendritic cell TIM-4 and T
cell TIM-1 abolished peanut extract specific TH2 polarization
and allergy in the intestine of BALB/c mice.49 Targeted
inhibition of the high affinity IgE-receptor via a mouse
Fc–Fc fusion protein suppressed the ability to sensitize
mast cells in vitro.50 A human homologue of this protein
prevented anaphylaxis to Ascaris in sensitized monkeys. Zhu
et al demonstrated that administration of a synthetic agonists
of Toll-like receptor 9 (immune modulatory oligonucleotide)
in a murine model had the capacity to switch peanut induced
skewing away from a TH2 immune responses toward a TH1
response accompanied by reduced inflammation in the gas-
trointestinal tract and anaphylaxis in both prevention and
treatment models.51 Using a combination of allergen specific
and nonspecific strategies are also under investigation. At
Duke, we are beginning a clinical trial using concurrent
anti-IgE therapy with peanut oral immunotherapy in the
treatment of peanut allergy.
CONCLUSION
The increasing prevalence of food allergy has brought
to the forefront the lack of treatment options and the impact
this disease has on patients, families, and the medical system.
There is an urgent need for more safe and effective treatment
options for these patients. Although genetic factors play a
role, the rising incidence of food allergy over the past few
decades must be explained by environmental variables. These
variables represent opportunities for potential therapies for
prevention or treatment of existing disease. As our knowl-
edge of the formation and loss of tolerance grows, new
immune pathways are emerging as possible targets of immu-
notherapy. Strategies manipulating these pathways are under
investigation and provide hope for food allergy patients and
their families.
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